TD Cowen Rates Twist Bioscience (TWST) buy, $89 Price Target

TD Cowen Keeps Buy Rating on Twist Bioscience

On June 15, 2026, TD Cowen analyst Brendan Smith reiterated a buy rating on Twist Bioscience Corporation NasdaqGS TWST, keeping an 89.00 dollar price target on the shares. The firm remains positive on the biotechnology provider as markets assess demand for synthetic genes and targeted next-generation sequencing tools.

Analysts Set New Price Targets

Other financial firms continue to adjust their outlooks on the company. On October 13, 2026, TD Cowen maintained a buy rating and raised its target to 190.00 dollars from 115.00 dollars. On October 12, 2026, Canaccord Genuity maintained a buy rating and lifted its target to 205.00 dollars from 120.00 dollars. On October 8, 2026, Jefferies initiated coverage with a hold rating and a 150.00 dollar price target. On October 7, 2026, Barclays maintained an overweight rating and raised its target to 215.00 dollars from 112.00 dollars. On October 1, 2026, Guggenheim maintained a buy rating and raised its target to 212.00 dollars from 107.00 dollars. On September 29, 2026, Leerink Partners maintained an outperform rating and raised its target to 190.00 dollars from 160.00 dollars. On September 18, 2026, BWS Financial maintained a sell rating with a 45.00 dollar target. On September 17, 2026, Leerink Partners maintained an outperform rating and raised its target to 160.00 dollars from 120.00 dollars. Overall, the stock carries a consensus buy recommendation with a mean price target of 109.58 dollars based on 12 analyst opinions, ranging from a low of 36.00 dollars to a high of 160.00 dollars.

Stock Price Range and Market Position

Twist Bioscience shares changed hands around 87.56 dollars on Monday. The stock has traded across a wide range over the past year, hitting a 52-week low of 23.30 dollars and reaching a high of 170.23 dollars. Shares currently sit above their 200-day moving average of 70.36 dollars, though they remain below their 50-day moving average of 119.81 dollars. The company carries a market capitalization of roughly 11.0 billion dollars.

Inside Twist Bioscience Operations

Headquartered in South San Francisco, California and led by CEO Dr. Emily Marine Leproust, Twist Bioscience manufactures and sells synthetic DNA-based products. Its offerings include synthetic genes, gene fragments, and oligo pools used in targeted next-generation sequencing, CRISPR gene editing, and drug discovery applications. The firm serves academic researchers, biotech outfits, and agricultural companies.

What to Watch at Twist Bioscience Corporation

Investors will look toward the company's next earnings report scheduled for November 16, 2026, for fresh figures on revenue growth and profit margins. Analyst target updates and broader sector sentiment will continue to guide near-term price action for the biotechnology firm.